This site makes use of Javascript, please enable your web browser to allow Javascript. Thank you.
Alumni | RSS | AA | Languages
 

RSS Feeds

RSS Feed - Life Sciences - Transactions - Kaye Scholer LLP

Current Feed: http://www.kayescholer.com/practice/rss.xml?p=life_sciences_transactions

> Change Feed

Kaye Scholer Honored With 14 Practice and 48 Lawyer Rankings in Chambers USA 2013 (05/24/13)

Adam H. Golden (05/24/13)

Adam H. Golden is a Partner in and Co-Chair of Kaye Scholer’s Corporate Department. His practice focuses on mergers and acquisitions, securities offerings, intellectual property licenses, joint ventures and other corporate partnering transactions. He has represented companies in the pharmaceutical and biotechnology, private equity, infrastructure, chemicals, consumer products, technology, software, healthcare services, medical devices, defense, finance and alternative asset management industries. Adam’s clients range in size from multibillion-dollar global businesses to emerging-stage companies.

Barry L. Dastin (05/16/13)

Barry Dastin is a Partner in the Corporate Department of Kaye Scholer LLP's Los Angeles office.

Joel I. Greenberg (05/06/13)

Joel Greenberg is the Senior Corporate Partner and Co-Chair of the Canada Group at Kaye Scholer. He concentrates in U.S. and cross-border mergers and acquisitions of public and private companies, representation of financial sponsors, and securities transactions. He also advises publicly held and private companies on a wide variety of corporate governance and day-to-day corporate as well as transactional matters. He is a former Chair (2006–2009) of the Committee on Mergers & Acquisitions of the American Bar Association Section of Business Law.

Dr. Gottfried Freier (04/29/13)

Dr. Gottfried Freier, Special Counsel bei Kaye Scholer, leitete von 2007 bis Mai 2012 als Managing Partner das Büro der Kanzlei in Frankfurt. Bevor er sich als Rechtsanwalt selbständig machte und 2001 zunächst Jones Day anschloss, war Dr. Freier von 1998 bis 2001 General Counsel Legal and Taxes von BASF Pharma mit weltweiter Verantwortung, sowie von 1985 bis 1998 in verschiedenen Funktionen Syndikusanwalt bei BASF (1985 - 1987 Patentabteilung, 1987 - 1993 Zentralabteilung Recht, 1993 - 1998 Zentralabteilung Steuern und Zölle). Aufgrund seiner langjährigen Tätigkeit als Unternehmensjurist in der Chemie- und der Pharmaindustrie hat sich bei der Mandantschaft von Dr. Gottfried Freier eine entsprechende Konzentration auf diese Branchen herausgebildet. Sein Beratungsspektrum umfasst vor allem die Bereiche Merger & Acquisitions, Gesellschaftsrecht, Technologietransaktionen (u.a. Lizenz- und Kooperationsverträge).

Jeffrey L. London (04/03/13)
Jeffrey London advises public and private companies in all areas of compensation design, including implementation of equity, equity-based and non-equity-based compensation arrangements, such as stock option plans, performance share plans, deferred compensation plans, restricted stock plans, phantom stock plans, gain-sharing programs and other types of short-term and long-term incentive programs. He counsels boards of directors and compensation committees in structuring compensation programs and agreements for themselves and their executive officers and negotiates employment and severance agreements and serves as "agent" on behalf of senior level executive officers. Mr. London also designs and implements qualified pension and profit-sharing plans (e.g., ESOPs, 401(k) plans, cash balance plans, defined benefit plans and profit-sharing plans), and counsels clients on the regulatory and administrative requirements of maintaining qualified plans. He advises clients on all aspects of welfare benefit plan design and administration, from health insurance programs to long-term disability programs to long-term care programs to severance arrangements, including counseling on such varied issues as COBRA, HIPAA, VEBAs, flexible spending accounts and cafeteria plans. Mr. London has represented clients in all aspects of ERISA litigation, including benefit claims, fiduciary breaches, and multi-employer pension plan withdrawal liability disputes.

Sandoz to Acquire Fougera Pharmaceuticals for $1.5B (03/27/13)

Subscribe

 
 
Praxisgruppen Practice Groups Industry Groups Regional Groups Pro Bono Berater Sozietät Karriere Diversity Pro Bono Newsroom Veranstaltungen Büros